Revolade (eltrombopag) study for children with aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial is for children and teenagers (ages 6 to 17) with aplastic anemia who are starting eltrombopag (Revolade) for the first time, taken together with ATG (a medicine that helps the immune system). The study will monitor how well the treatment works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- You have aplastic anemia (a condition where your bone marrow doesn't make enough blood cells).
- You are about to start eltrombopag (Revolade) for the first time, and it will be combined with a medicine called ATG (anti-thymocyte globulin).
- You have not had ATG alone (without eltrombopag) before.
- You do not have a type of aplastic anemia that is passed down through families (congenital).
- You do not have a blood disorder called myelodysplastic syndrome (MDS).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called avatrombopag for people with aplastic anemia whose blood counts have not improved with standard treatments. Avatrombopag is designed to help the body produce more platelets, which may reduce the risk of bleeding.
This trial tests adding romiplostim to standard care for severe aplastic anemia (a condition where the bone marrow doesn't make enough blood cells) in patients aged 2 to 21. It aims to see if this combination improves blood cell counts in those newly diagnosed or whose disease has come back or not responded to prior treatment.
This trial tests a drug called romiplostim (Nplate) for patients whose aplastic anemia—a rare blood disorder where the bone marrow stops making enough blood cells—didn't improve after cancer treatment and hasn't responded to other medications. The drug may help your bone marrow produce more blood cells.
This trial tests a new treatment to help restore blood cell production in people with aplastic anemia whose bone marrow isn't working well after a stem cell transplant or other therapies. The goal is to improve blood counts and reduce the need for transfusions or support medications.
This trial tests a new platelet-raising medicine, avatrombopag, in children with ITP who have already tried eltrombopag. It aims to see if switching to avatrombopag can safely increase platelet counts and reduce bleeding.
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.